Expert Point of View: Marjorie G. Zauderer, MD and Andrew D. Seidman, MD


Get Permission

Commenting on the ganetespib study, Marjorie G. Zauderer, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York, said that this first-in-class study suggests efficacy and represents a potential advance in lung cancer treatment. “We haven’t had any advances in a long time. We await the results of the phase III trial,” she said.

Andrew D. Seidman, MD, another medical oncologist from Memorial Sloan-Kettering Cancer Center, said that heat shock protein 90 inhibitors are also being studied in breast cancer and other cancers. “This approach of harnessing a chaperone protein is applicable to other tumor types,” he stated. ■

Disclosure: Drs. Zauderer and Seidman reported no potential conflicts of interest.


Related Articles

First Positive Trial of Heat Shock Protein 90 Inhibitor in Lung Cancer That Has Progressed after First-line Therapy

The investigational heat shock protein (Hsp)90 inhibitor ganetespib plus docetaxel extended overall survival compared with docetaxel alone as second-line therapy in patients with advanced non–small cell adenocarcinoma of the lung that had progressed on first-line therapy in the randomized phase II...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.